Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 19/20 | 0.44 |
| ▸ | CHUK | O15111 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621272 | 0.93 | IKBKB (0.39) | IKBKBCHUKHRH3BTKCSF1R | |
| SCHEMBL619148 | 0.87 | IKBKB (0.60) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL621270 | 0.85 | IKBKB (0.61) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL621457 | 0.84 | IKBKB (0.61) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL618927 | 0.83 | IKBKB (0.48) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL619145 | 0.83 | IKBKB (0.62) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL621081 | 0.82 | IKBKB (0.62) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL618765 | 0.81 | IKBKB (0.56) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL619147 | 0.81 | IKBKB (0.51) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL14049738 | 0.80 | IKBKB (0.41) | IKBKBCHUKHRH3BTKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372875-B2 | Indole carboxamides as IKK2 inhibitors | GlaxoSmithKline, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372875-B2 | Indole carboxamides as IKK2 inhibitors | GlaxoSmithKline, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372875-B2 | Indole carboxamides as IKK2 inhibitors | GlaxoSmithKline, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2012-02-16 | — | — | US | disclosed |
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2012-02-16 | — | — | US | disclosed |
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2012-02-16 | — | — | US | disclosed |
| US-8071584-B2 | Indole carboxamides as IKK2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071584-B2 | Indole carboxamides as IKK2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071584-B2 | Indole carboxamides as IKK2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
| EP-2139322-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | Smithkline Beecham Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008118724-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | IKBKB 8/4885CHUK 14/4885HRH3 129/4885 |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | IKBKB 8/4885CHUK 14/4885HRH3 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.